Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Pharmacology

High-Dosage Cefazolin Achieves Sufficient Cerebrospinal Diffusion To Treat an External Ventricular Drainage-Related Staphylococcus aureus Ventriculitis

Matthieu Grégoire, Benjamin Gaborit, Colin Deschanvres, Raphaël Lecomte, Guillaume Deslandes, Éric Dailly, Xavier Ambrosi, Ronan Bellouard, Nathalie Asseray, Karim Lakhal, David Boutoille
Matthieu Grégoire
aClinical Pharmacology Department, CHU Nantes, Nantes, France
bUMR Inserm 1235 The Enteric Nervous System in Gut and Brain Disorders, University of Nantes, Nantes, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Matthieu Grégoire
Benjamin Gaborit
cInfectious Diseases Department, CHU Nantes and CIC 1413, Inserm, Nantes, France
dEA 3826 Thérapeutiques Cliniques et Expérimentales des Infections, University of Nantes, Nantes, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Colin Deschanvres
cInfectious Diseases Department, CHU Nantes and CIC 1413, Inserm, Nantes, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Raphaël Lecomte
cInfectious Diseases Department, CHU Nantes and CIC 1413, Inserm, Nantes, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guillaume Deslandes
aClinical Pharmacology Department, CHU Nantes, Nantes, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Éric Dailly
aClinical Pharmacology Department, CHU Nantes, Nantes, France
eEE1701 Microbiotas, Hosts, Antibiotics and Bacterial Resistances, University of Nantes, Nantes, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xavier Ambrosi
fRéanimation Chirurgicale Polyvalente, Service d’Anesthésie-Réanimation, Hôpital Laënnec, CHU Nantes, Nantes, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ronan Bellouard
aClinical Pharmacology Department, CHU Nantes, Nantes, France
eEE1701 Microbiotas, Hosts, Antibiotics and Bacterial Resistances, University of Nantes, Nantes, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nathalie Asseray
cInfectious Diseases Department, CHU Nantes and CIC 1413, Inserm, Nantes, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karim Lakhal
fRéanimation Chirurgicale Polyvalente, Service d’Anesthésie-Réanimation, Hôpital Laënnec, CHU Nantes, Nantes, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Boutoille
cInfectious Diseases Department, CHU Nantes and CIC 1413, Inserm, Nantes, France
dEA 3826 Thérapeutiques Cliniques et Expérimentales des Infections, University of Nantes, Nantes, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.01844-18
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

A patient received continuous infusion of cefazolin 10 g then 8 g daily for an external ventricular drainage-related methicillin-susceptible Staphylococcus aureus (MSSA) ventriculitis. Median free concentrations in the cerebrospinal fluid were 11.9 and 6.1 mg/liter after 10- and 8-g doses, respectively. Free concentrations in the cerebrospinal fluid were always above the MIC usually displayed by methicillin-susceptible Staphylococcus aureus (MSSA) isolates. These results support the use of high-dose cefazolin to achieve sufficient meningeal concentrations.

INTRODUCTION

Recent studies showed that cefazolin is at least as effective as oxacillin or nafcillin for the treatment of severe methicillin-susceptible Staphylococcus aureus (MSSA) infections (1, 2). External ventricular drainage (EVD)-related ventriculitis and meningitis are mostly caused by Gram-positive cocci and particularly staphylococci (3). Owing to the poor diffusion of oxacillin and nafcillin into the meningeal compartment, cefotaxime, fosfomycin, and rifampin are currently used in this indication (4). Despite in vitro activity, the use of cefazolin for MSSA-related meningitis is limited because of its supposed weak meningeal diffusion due to a high level of protein binding (∼85%) associated with moderate lipophilicity (5). Regarding the antistaphylococcal activity of this first-generation cephalosporin, data about the use of cefazolin in EVD-related ventriculitis or meningitis are required.

We herein describe the unique case of a patient treated by continuous intravenous infusion of cefazolin at high dose (8 to 10 g daily) for an EVD-related MSSA ventriculitis.

A 42-year-old patient (weight, 67 kg) with no medical history was hospitalized for a subarachnoid hemorrhage requiring an EVD. At day 7, neurological impairment led to the diagnosis of ventriculitis: glycorrhachia was <1 mmol/liter and cerebrospinal fluid (CSF) lactate was 8 mmol/liter. An empirical combination of intravenous cefotaxime and linezolid was introduced. Two days later, as the CSF grew MSSA, the antimicrobial therapy relied on a continuous intravenous infusion of cefazolin 10 g plus levofloxacin 750 mg daily. The profile of antibiotic susceptibility was determined by the Vitek* 2 automated system (bioMérieux, France): MIC was 0.5 mg/liter for oxacillin and 1.5 mg/liter for cefotaxime. Moreover, this strain was resistant to co-trimoxazole and rifampin. CSF collected at the time of the antibiotic switch (i.e., after 2 days of antimicrobial therapy) was still positive for S. aureus. Thereafter, CSF was collected every 48 h until sterilization was achieved, which occurred 48 h after initiation of cefazolin. Then, the EVD was changed and was removed 13 days later after a progressive weaning. All the bacteriological cultures performed afterward remained sterile until the end of treatment, 6 weeks later. Glomerular filtration rate estimated by Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) progressively increased from 60 ml/min per 1.73 m2 at cefazolin initiation to 106 ml/min per 1.73 m2 after 6 weeks.

CSF and blood samples were simultaneously collected from day 2 after cefazolin initiation to day 21. Plasma samples were obtained by centrifugation, and ultrafiltrates were obtained after CSF or plasma centrifugation at 37°C into a Millipore UFC503024 Amicon Ultra-0.5 (Millipore Merck, Cork, Ireland) for 20 min at 14,000 × g. Cefazolin concentrations were measured in CSF, plasma, and ultrafiltrates by a liquid-chromatography mass-spectrometry-validated assay. The limit of quantitation was 2 mg/liter in CSF, plasma, and ultrafiltrates. Clinical and biological data were collected during patient hospitalization. Written informed consent was obtained from the patient for this publication.

Median total plasma concentrations at steady state (Css) were 118 mg/liter with the 10-g dose and 66.5 mg/liter with the 8-g dose (Fig. 1). The patient was switched to a lower dose because of elevated plasma Css after a 10-g daily dose. These results are presented in Table 1. Median free fraction was 22% after a 10-g dose but only 13% after an 8-g dose. Conversely, diffusion of the free fraction through the blood-brain barrier showed significant intraindividual variability, and CSF/plasma free Css (fCss) ratio decreased with the dose, from 73% after 8 g to 54% after 10 g. fCss in CSF was 11.9 mg/liter after a 10-g dose and 6.1 after an 8-g dose. Cefazolin, as a β-lactam, displays time-dependent activity. Hence, its efficacy relies on the percentage of time with a free drug concentration above the MIC of the bacteria (% fT>MIC) over a dosing interval. Considering that MSSA strains usually display MICs of ≤2 mg/liter according to the epidemiological cutoff values of the European Committee on Antimicrobial Susceptibility Testing, the fCss in CSF in this study was above the MIC throughout the treatment, as usually targeted (100% fT>MIC) (6).

FIG 1
  • Open in new tab
  • Download powerpoint
FIG 1

Pharmacokinetics of cefazolin in cerebrospinal fluid (squares) and plasma (circles) after a 10-g dose followed by an 8-g dose. Total concentrations are represented by continuous lines and unbound by dashed lines.

View this table:
  • View inline
  • View popup
TABLE 1

Cefazolin concentrations in plasma and cerebrospinal fluid after 8 or 10 g daily administered in continuous infusion

In this case of a patient treated with continuous infusion of cefazolin for an EVD-related ventriculitis, the targeted fCss in the CSF above MIC was achieved for MSSA strains, which usually display MICs of ≤2 mg/liter (100% fT>MIC), provided that a high dose (at least 8 g/day administered by continuous infusion) was used. During EVD-related ventriculitis and meningitis, the degree of meningeal inflammation is variable and known to have a large impact on antibiotic penetration (7, 8). This case highlights the important intraindividual variability of cefazolin plasma concentrations (particularly free-fraction concentration in critically ill patients) and the variability of CSF diffusion in case of infection with inconstant inflammation. In addition, it demonstrates the lack of linearity of the dose-concentration relationship in critically ill patients (9). Two previous studies reported high cefazolin CSF concentrations in patients not treated for meningitis and experiencing neurological adverse events. (10, 11). Of note, to the best of our knowledge, cefazolin pharmacokinetics in patients treated for meningeal infection has not been reported. Of course, our results need to be confirmed by a larger pharmacokinetics study. Moreover, a specific clinical investigation should address whether a cefazolin-based treatment of MSSA meningitis is suitable, because the success of this approach may depend on the inoculum effect, even if cefazolin meningeal diffusion is sufficient (12).

These preliminary findings show that cefazolin may be an alternative to cefotaxime, fosfomycin, or rifampin in EVD ventriculitis or meningitis. Indeed, its meningeal diffusion appeared to be sufficient. However, in critically ill patients, inter- and intraindividual variations in plasma and CSF cefazolin concentrations mandate close monitoring of these concentrations.

ACKNOWLEDGMENTS

K.L. received, during the past 3 years, lecture fees from Medtronic, congress registration fees from Sanofi Aventis, and travel fees from MSD France, Novex Pharma, and Gilead Sciences.

We have no conflicts of interest to declare.

FOOTNOTES

    • Received 28 August 2018.
    • Returned for modification 17 October 2018.
    • Accepted 1 November 2018.
    • Accepted manuscript posted online 12 November 2018.
  • Copyright © 2019 American Society for Microbiology.

All Rights Reserved.

REFERENCES

  1. 1.↵
    1. McDanel JS,
    2. Roghmann M-C,
    3. Perencevich EN,
    4. Ohl ME,
    5. Goto M,
    6. Livorsi DJ,
    7. Jones M,
    8. Albertson JP,
    9. Nair R,
    10. O'Shea AMJ,
    11. Schweizer ML
    . 2017. Comparative effectiveness of cefazolin versus nafcillin or oxacillin for treatment of methicillin-susceptible Staphylococcus aureus infections complicated by bacteremia: a nationwide cohort study. Clin Infect Dis 65:100–106. doi:10.1093/cid/cix287.
    OpenUrlCrossRef
  2. 2.↵
    1. Pollett S,
    2. Baxi SM,
    3. Rutherford GW,
    4. Doernberg SB,
    5. Bacchetti P,
    6. Chambers HF
    . 2016. Cefazolin versus nafcillin for methicillin-sensitive Staphylococcus aureus bloodstream infection in a California tertiary medical center. Antimicrob Agents Chemother 60:4684–4689. doi:10.1128/AAC.00243-16.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Korinek A-M,
    2. Reina M,
    3. Boch AL,
    4. Rivera AO,
    5. De Bels D,
    6. Puybasset L
    . 2005. Prevention of external ventricular drain-related ventriculitis. Acta Neurochir (Wien) 147:39–45. doi:10.1007/s00701-004-0416-z.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Beer R,
    2. Lackner P,
    3. Pfausler B,
    4. Schmutzhard E
    . 2008. Nosocomial ventriculitis and meningitis in neurocritical care patients. J Neurol 255:1617–1624. doi:10.1007/s00415-008-0059-8.
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.↵
    1. Radouane A,
    2. Péhourcq F,
    3. Tramu G,
    4. Creppy EE,
    5. Bannwarth B
    . 1996. Influence of lipophilicity on the diffusion of cephalosporins into the cerebrospinal fluid. Fundam Clin Pharmacol 10:309–313. doi:10.1111/j.1472-8206.1996.tb00311.x.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Mouton JW,
    2. Muller AE,
    3. Canton R,
    4. Giske CG,
    5. Kahlmeter G,
    6. Turnidge J
    . 2018. MIC-based dose adjustment: facts and fables. J Antimicrob Chemother 73:564–568. doi:10.1093/jac/dkx427.
    OpenUrlCrossRef
  7. 7.↵
    1. Varatharaj A,
    2. Galea I
    . 2017. The blood-brain barrier in systemic inflammation. Brain Behav Immun 60:1–12. doi:10.1016/j.bbi.2016.03.010.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Nau R,
    2. Sörgel F,
    3. Eiffert H
    . 2010. Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections. Clin Microbiol Rev 23:858–883. doi:10.1128/CMR.00007-10.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Kumta N,
    2. Roberts JA,
    3. Lipman J,
    4. Cotta MO
    . 2018. Antibiotic distribution into cerebrospinal fluid: can dosing safely account for drug and disease factors in the treatment of ventriculostomy-associated infections? Clin Pharmacokinet 57:439–454. doi:10.1007/s40262-017-0588-3.
    OpenUrlCrossRef
  10. 10.↵
    1. Moore TD,
    2. Bechtel TP,
    3. Ayers LW
    . 1981. Effect of multidose therapy on cerebrospinal fluid penetration of cefazolin. Am J Hosp Pharm 38:1496–1499.
    OpenUrlAbstract
  11. 11.↵
    1. Bechtel TP,
    2. Slaughter RL,
    3. Moore TD
    . 1980. Seizures associated with high cerebrospinal fluid concentrations of cefazolin. Am J Hosp Pharm 37:271–273.
    OpenUrlAbstract
  12. 12.↵
    1. Saeki M,
    2. Shinagawa M,
    3. Yakuwa Y,
    4. Nirasawa S,
    5. Sato Y,
    6. Yanagihara N,
    7. Takahashi S
    . 2018. Inoculum effect of high concentrations of methicillin-susceptible Staphylococcus aureus on the efficacy of cefazolin and other beta-lactams. J Infect Chemother 24:212–215. doi:10.1016/j.jiac.2017.10.021.
    OpenUrlCrossRef
PreviousNext
Back to top
Download PDF
Citation Tools
High-Dosage Cefazolin Achieves Sufficient Cerebrospinal Diffusion To Treat an External Ventricular Drainage-Related Staphylococcus aureus Ventriculitis
Matthieu Grégoire, Benjamin Gaborit, Colin Deschanvres, Raphaël Lecomte, Guillaume Deslandes, Éric Dailly, Xavier Ambrosi, Ronan Bellouard, Nathalie Asseray, Karim Lakhal, David Boutoille
Antimicrobial Agents and Chemotherapy Jan 2019, 63 (2) e01844-18; DOI: 10.1128/AAC.01844-18

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
High-Dosage Cefazolin Achieves Sufficient Cerebrospinal Diffusion To Treat an External Ventricular Drainage-Related Staphylococcus aureus Ventriculitis
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
High-Dosage Cefazolin Achieves Sufficient Cerebrospinal Diffusion To Treat an External Ventricular Drainage-Related Staphylococcus aureus Ventriculitis
Matthieu Grégoire, Benjamin Gaborit, Colin Deschanvres, Raphaël Lecomte, Guillaume Deslandes, Éric Dailly, Xavier Ambrosi, Ronan Bellouard, Nathalie Asseray, Karim Lakhal, David Boutoille
Antimicrobial Agents and Chemotherapy Jan 2019, 63 (2) e01844-18; DOI: 10.1128/AAC.01844-18
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • INTRODUCTION
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

cefazolin
cerebrospinal fluid
healthcare-associated infection
meningitis
pharmacokinetics

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596